182 related articles for article (PubMed ID: 19559109)
1. Improved antibiotic-free DNA vaccine vectors utilizing a novel RNA based plasmid selection system.
Luke J; Carnes AE; Hodgson CP; Williams JA
Vaccine; 2009 Oct; 27(46):6454-9. PubMed ID: 19559109
[TBL] [Abstract][Full Text] [Related]
2. Critical design criteria for minimal antibiotic-free plasmid vectors necessary to combine robust RNA Pol II and Pol III-mediated eukaryotic expression with high bacterial production yields.
Carnes AE; Luke JM; Vincent JM; Anderson S; Schukar A; Hodgson CP; Williams JA
J Gene Med; 2010 Oct; 12(10):818-31. PubMed ID: 20806425
[TBL] [Abstract][Full Text] [Related]
3. The antibiotic resistance-free mammalian expression plasmid vector pPAL for development of third generation vaccines.
Alcolea PJ; Alonso A; Larraga V
Plasmid; 2019 Jan; 101():35-42. PubMed ID: 30529129
[TBL] [Abstract][Full Text] [Related]
4. Development of antibiotic-free selection system for safer DNA vaccination.
Luke JM; Carnes AE; Williams JA
Methods Mol Biol; 2014; 1143():91-111. PubMed ID: 24715283
[TBL] [Abstract][Full Text] [Related]
5. A novel bi-functional DNA vaccine expressing VP1 protein and producing antisense RNA targeted to 5'UTR of foot-and-mouth disease virus can induce both rapid inhibitory effect and specific immune response in mice.
Yang B; Lan X; Li X; Yin X; Li B; Han X; Li Y; Zhang Z; Liu J
Vaccine; 2008 Oct; 26(43):5477-83. PubMed ID: 18694793
[TBL] [Abstract][Full Text] [Related]
6. Improvement of DNA vaccine immunogenicity by a dual antigen expression system.
Sasaki S; Takeshita F; Oikawa T; Kojima Y; Xin KQ; Okuda K; Ishii N
Biochem Biophys Res Commun; 2004 Feb; 315(1):38-43. PubMed ID: 15013422
[TBL] [Abstract][Full Text] [Related]
7. Diverse plasmid DNA vectors by directed molecular evolution of cytomegalovirus promoters.
Wright A; Semyonov A; Dawes G; Crameri A; Lyons R; Stemmer WP; Apt D; Punnonen J
Hum Gene Ther; 2005 Jul; 16(7):881-92. PubMed ID: 16000069
[TBL] [Abstract][Full Text] [Related]
8. Increased immunogenicity of a DNA-launched Venezuelan equine encephalitis virus-based replicon DNA vaccine.
Ljungberg K; Whitmore AC; Fluet ME; Moran TP; Shabman RS; Collier ML; Kraus AA; Thompson JM; Montefiori DC; Beard C; Johnston RE
J Virol; 2007 Dec; 81(24):13412-23. PubMed ID: 17913817
[TBL] [Abstract][Full Text] [Related]
9. Identification and characterization of IS1 transposition in plasmid amplification mutants of E. coli clones producing DNA vaccines.
Prather KL; Edmonds MC; Herod JW
Appl Microbiol Biotechnol; 2006 Dec; 73(4):815-26. PubMed ID: 16941177
[TBL] [Abstract][Full Text] [Related]
10. Improving DNA vaccine performance through vector design.
Williams JA
Curr Gene Ther; 2014; 14(3):170-89. PubMed ID: 25142448
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant effects of plasmid-generated hairpin RNA molecules on DNA vaccination.
Li D; Liu Y; Zhang Y; Xu J; Hong K; Sun M; Shao Y
Vaccine; 2007 Sep; 25(39-40):6992-7000. PubMed ID: 17716788
[TBL] [Abstract][Full Text] [Related]
12. Impact of a Plasmid DNA-Based Alphavirus Vaccine on Immunization Efficiency.
Lundstrom K
Methods Mol Biol; 2021; 2197():33-47. PubMed ID: 32827131
[TBL] [Abstract][Full Text] [Related]
13. The pYC plasmids, a series of cassette-based yeast plasmid vectors providing means of counter-selection.
Olesen K; Franke Johannesen P; Hoffmann L; Bech Sorensen S; Gjermansen C; Hansen J
Yeast; 2000 Aug; 16(11):1035-43. PubMed ID: 10923025
[TBL] [Abstract][Full Text] [Related]
14. Improved antibiotic-free plasmid vector design by incorporation of transient expression enhancers.
Luke JM; Vincent JM; Du SX; Gerdemann U; Leen AM; Whalen RG; Hodgson CP; Williams JA
Gene Ther; 2011 Apr; 18(4):334-43. PubMed ID: 21107439
[TBL] [Abstract][Full Text] [Related]
15. Main features of DNA-based immunization vectors.
Azevedo V; Levitus G; Miyoshi A; Cândido AL; Goes AM; Oliveira SC
Braz J Med Biol Res; 1999 Feb; 32(2):147-53. PubMed ID: 10347749
[TBL] [Abstract][Full Text] [Related]
16. DNA immunisation with minimalistic expression constructs.
Moreno S; López-Fuertes L; Vila-Coro AJ; Sack F; Smith CA; Konig SA; Wittig B; Schroff M; Juhls C; Junghans C; Timón M
Vaccine; 2004 Apr; 22(13-14):1709-16. PubMed ID: 15068854
[TBL] [Abstract][Full Text] [Related]
17. Comparison of immune responses induced in mice by vaccination with DNA vaccine constructs expressing mycobacterial antigen 85A and interleukin-21 and Bacillus Galmette-Guérin.
Dou J; Tang Q; Zhao F; Chu L; Chen J; Cao M; Liu C; Wang Y; Li Y; Li JL
Immunol Invest; 2008; 37(2):113-27. PubMed ID: 18300037
[TBL] [Abstract][Full Text] [Related]
18. Serum amyloid P component facilitates DNA clearance and inhibits plasmid transfection: implications for human DNA vaccine.
Wang Y; Guo Y; Wang X; Huang J; Shang J; Sun S
Gene Ther; 2012 Jan; 19(1):70-7. PubMed ID: 21544098
[TBL] [Abstract][Full Text] [Related]
19. Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production.
Williams JA; Carnes AE; Hodgson CP
Biotechnol Adv; 2009; 27(4):353-70. PubMed ID: 19233255
[TBL] [Abstract][Full Text] [Related]
20. A pestivirus DNA vaccine based on a non-antibiotic resistance Escherichia coli essential gene marker.
El-Attar LM; Scott S; Goh S; Good L
Vaccine; 2012 Feb; 30(9):1702-9. PubMed ID: 22212129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
